<p>Spyre Therapeutics, Inc. (NASDAQ:SYRE - 获取免费报告) 的股价在周二创下 52 周新低。该公司股价最低交易至 20.25 美元，最后交易价为 20.09 美元，成交量为 133465 股。该股票此前收盘价为 21.26 美元。</p>
<p>获取 <strong>Spyre Therapeutics</strong> 的提醒：</p>
<h2>华尔街分析师观点</h2>
<p>多位分析师最近对 SYRE 股票发表了评论。罗伯特·W·贝尔德将 Spyre Therapeutics 的目标价从 50.00 美元上调至 65.00 美元，并在 11 月 13 日的报告中给予该股票 “跑赢大盘” 的评级。高盛集团在 2 月 18 日的研究报告中将 Spyre Therapeutics 的评级上调至 “强力买入”。最后，Wedbush 在 1 月 13 日的研究报告中重申了 “跑赢大盘” 的评级，并对 Spyre Therapeutics 的股票设定了 65.00 美元的目标价。七位股票研究分析师对该股票给予了买入评级，一位分析师给予了强力买入评级。根据 MarketBeat.com 的数据，Spyre Therapeutics 目前的共识评级为 “买入”，平均目标价为 54.83 美元。</p>
<p><strong>查看我们关于 SYRE 的最新报告</strong></p>
<h2>Spyre Therapeutics 股价下跌 4.2%</h2>
<p>该公司的 50 日移动平均线为 22.72 美元，200 日移动平均线为 26.97 美元。该公司的市值为 10.5 亿美元，市盈率为-2.72，贝塔值为 2.85。</p>
<h2>机构投资者对 Spyre Therapeutics 的看法</h2>
<p>多家对冲基金最近买入和卖出了 SYRE 的股票。Driehaus Capital Management LLC 在第四季度将其在 Spyre Therapeutics 的股份增加了 308.1%。Driehaus Capital Management LLC 目前拥有 2803655 股该公司的股票，价值 65269000 美元，此前在上个季度增持了 2116575 股。FMR LLC 在第四季度将其在 Spyre Therapeutics 的持仓增加了 15.4%。FMR LLC 目前拥有 8801266 股该公司的股票，价值 204893000 美元，此前在上个季度增持了 1177385 股。Jefferies Financial Group Inc.在第四季度将其在 Spyre Therapeutics 的持股增加了 167.6%。Jefferies Financial Group Inc.目前拥有 1216954 股该公司的股票，价值 28331000 美元，此前在上个季度增持了 762147 股。Wellington Management Group LLP 在第三季度将其在 Spyre Therapeutics 的持股增加了 89.4%。Wellington Management Group LLP 目前拥有 1507200 股该公司的股票，价值 44327000 美元，此前在上个季度增持了 711254 股。最后，Boxer Capital Management LLC 在第四季度购买了 Spyre Therapeutics 的新头寸，价值 10864000 美元。目前 80.39% 的股票由机构投资者持有。</p>
<h2>Spyre Therapeutics 公司简介</h2>
<p>(获取免费报告)</p>
<p>Spyre Therapeutics, Inc.是一家处于临床前阶段的生物技术公司，专注于为患有炎症性肠病（IBD）的患者开发治疗方案。它开发的 SPY001 是一种人源单克隆免疫球蛋白 G1 抗体，旨在选择性结合 a4ß7 整合素，正在开发用于治疗 IBD（溃疡性结肠炎和克罗恩病）。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 Spyre Therapeutics</li>
<li>如何利用高贝塔股票最大化投资收益</li>
<li>NVIDIA 股票：科技动荡时期的市场晴雨表</li>
<li>银行股票 - 最值得投资的银行股票</li>
<li>Palantir 股票接近熊市区域 - 原因及下一步？</li>
<li>如何有效使用 MarketBeat 评级筛选器</li>
<li>家得宝迎来转机：今年可能创下新高</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Spyre Therapeutics 吗？</h2>
<p>在考虑 Spyre Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 Spyre Therapeutics 并不在名单上。</p>
<p>虽然 Spyre Therapeutics 目前在分析师中获得了 “买入” 评级，但顶级分析师认为这五只股票更值得买入。</p>
<p>在这里查看这五只股票</p>

SYRE

<p>Spyre Therapeutics（纳斯达克代码：SYRE）创下 52 周新低，报 20.09 美元，较前一交易日收盘价 21.26 美元下跌。分析师意见不一，罗伯特·W·贝尔德将其目标价上调至 65.00 美元，并维持 “跑赢大盘” 评级。高盛将其评级上调至 “强力买入”。机构投资者持有该股票的 80.39%，Driehaus Capital 和 FMR LLC 的持股比例显著增加。该公司专注于开发针对炎症性肠病（IBD）的治疗药物</p>

<p>Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report)'s stock price hit a new 52-week low on Tuesday . The company traded as low as $20.25 and last traded at $20.09, with a volume of 133465 shares traded. The stock had previously closed at $21.26.</p>
<div class="lb-trans"><p>Spyre Therapeutics, Inc. (NASDAQ:SYRE - 获取免费报告) 的股价在周二创下 52 周新低。该公司股价最低交易至 20.25 美元，最后交易价为 20.09 美元，成交量为 133465 股。该股票此前收盘价为 21.26 美元。</p>
</div><p>Get <strong>Spyre Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Spyre Therapeutics</strong> 的提醒：</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>A number of analysts recently commented on SYRE shares. Robert W. Baird lifted their price target on Spyre Therapeutics from $50.00 to $65.00 and gave the stock an &#34;outperform&#34; rating in a report on Wednesday, November 13th. The Goldman Sachs Group raised Spyre Therapeutics to a &#34;strong-buy&#34; rating in a research note on Tuesday, February 18th. Finally, Wedbush restated an &#34;outperform&#34; rating and issued a $65.00 price target on shares of Spyre Therapeutics in a research note on Monday, January 13th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Spyre Therapeutics presently has a consensus rating of &#34;Buy&#34; and an average target price of $54.83.</p>
<div class="lb-trans"><p>多位分析师最近对 SYRE 股票发表了评论。罗伯特·W·贝尔德将 Spyre Therapeutics 的目标价从 50.00 美元上调至 65.00 美元，并在 11 月 13 日的报告中给予该股票 “跑赢大盘” 的评级。高盛集团在 2 月 18 日的研究报告中将 Spyre Therapeutics 的评级上调至 “强力买入”。最后，Wedbush 在 1 月 13 日的研究报告中重申了 “跑赢大盘” 的评级，并对 Spyre Therapeutics 的股票设定了 65.00 美元的目标价。七位股票研究分析师对该股票给予了买入评级，一位分析师给予了强力买入评级。根据 MarketBeat.com 的数据，Spyre Therapeutics 目前的共识评级为 “买入”，平均目标价为 54.83 美元。</p>
</div><p><strong>View Our Latest Report on SYRE</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 SYRE 的最新报告</strong></p>
</div><h2>Spyre Therapeutics Trading Down 4.2 %</h2>
<div class="lb-trans"><h2>Spyre Therapeutics 股价下跌 4.2%</h2>
</div><p>The company has a 50-day moving average of $22.72 and a 200-day moving average of $26.97. The firm has a market capitalization of $1.05 billion, a price-to-earnings ratio of -2.72 and a beta of 2.85.</p>
<div class="lb-trans"><p>该公司的 50 日移动平均线为 22.72 美元，200 日移动平均线为 26.97 美元。该公司的市值为 10.5 亿美元，市盈率为-2.72，贝塔值为 2.85。</p>
</div><h2>Institutional Investors Weigh In On Spyre Therapeutics</h2>
<div class="lb-trans"><h2>机构投资者对 Spyre Therapeutics 的看法</h2>
</div><p>A number of hedge funds have recently bought and sold shares of SYRE. Driehaus Capital Management LLC increased its stake in shares of Spyre Therapeutics by 308.1% in the 4th quarter. Driehaus Capital Management LLC now owns 2,803,655 shares of the company's stock valued at $65,269,000 after acquiring an additional 2,116,575 shares during the last quarter. FMR LLC lifted its position in shares of Spyre Therapeutics by 15.4% during the 4th quarter. FMR LLC now owns 8,801,266 shares of the company's stock worth $204,893,000 after buying an additional 1,177,385 shares during the last quarter. Jefferies Financial Group Inc. increased its holdings in Spyre Therapeutics by 167.6% in the 4th quarter. Jefferies Financial Group Inc. now owns 1,216,954 shares of the company's stock worth $28,331,000 after purchasing an additional 762,147 shares in the last quarter. Wellington Management Group LLP raised its holdings in Spyre Therapeutics by 89.4% during the 3rd quarter. Wellington Management Group LLP now owns 1,507,200 shares of the company's stock worth $44,327,000 after purchasing an additional 711,254 shares during the last quarter. Finally, Boxer Capital Management LLC bought a new position in Spyre Therapeutics during the fourth quarter worth $10,864,000. 80.39% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>多家对冲基金最近买入和卖出了 SYRE 的股票。Driehaus Capital Management LLC 在第四季度将其在 Spyre Therapeutics 的股份增加了 308.1%。Driehaus Capital Management LLC 目前拥有 2803655 股该公司的股票，价值 65269000 美元，此前在上个季度增持了 2116575 股。FMR LLC 在第四季度将其在 Spyre Therapeutics 的持仓增加了 15.4%。FMR LLC 目前拥有 8801266 股该公司的股票，价值 204893000 美元，此前在上个季度增持了 1177385 股。Jefferies Financial Group Inc.在第四季度将其在 Spyre Therapeutics 的持股增加了 167.6%。Jefferies Financial Group Inc.目前拥有 1216954 股该公司的股票，价值 28331000 美元，此前在上个季度增持了 762147 股。Wellington Management Group LLP 在第三季度将其在 Spyre Therapeutics 的持股增加了 89.4%。Wellington Management Group LLP 目前拥有 1507200 股该公司的股票，价值 44327000 美元，此前在上个季度增持了 711254 股。最后，Boxer Capital Management LLC 在第四季度购买了 Spyre Therapeutics 的新头寸，价值 10864000 美元。目前 80.39% 的股票由机构投资者持有。</p>
</div><h2>Spyre Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Spyre Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).</p>
<div class="lb-trans"><p>Spyre Therapeutics, Inc.是一家处于临床前阶段的生物技术公司，专注于为患有炎症性肠病（IBD）的患者开发治疗方案。它开发的 SPY001 是一种人源单克隆免疫球蛋白 G1 抗体，旨在选择性结合 a4ß7 整合素，正在开发用于治疗 IBD（溃疡性结肠炎和克罗恩病）。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Spyre Therapeutics</li>
<li>How to Use High Beta Stocks to Maximize Your Investing Profits</li>
<li>NVIDIA Stock: A Market Barometer in Tech’s Turbulent Times</li>
<li>Bank Stocks - Best Bank Stocks to Invest In</li>
<li>Palantir Stock Nears Bear Market Territory - Why and What’s Next?</li>
<li>How to Effectively Use the MarketBeat Ratings Screener</li>
<li>Home Depot Turns a Corner: New Highs Likely This Year</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Spyre Therapeutics</li>
<li>如何利用高贝塔股票最大化投资收益</li>
<li>NVIDIA 股票：科技动荡时期的市场晴雨表</li>
<li>银行股票 - 最值得投资的银行股票</li>
<li>Palantir 股票接近熊市区域 - 原因及下一步？</li>
<li>如何有效使用 MarketBeat 评级筛选器</li>
<li>家得宝迎来转机：今年可能创下新高</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Spyre Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Spyre Therapeutics 吗？</h2>
</div><p>Before you consider Spyre Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Spyre Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Spyre Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 Spyre Therapeutics 并不在名单上。</p>
</div><p>While Spyre Therapeutics currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Spyre Therapeutics 目前在分析师中获得了 “买入” 评级，但顶级分析师认为这五只股票更值得买入。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Spyre Therapeutics（纳斯达克股票代码：SYRE）创下一年新低 - 你应该卖出吗？